LLY
Eli Lilly & Co.
$1255.20
장중 · Vol 253.3K · 52주 $712.05–$1292.65 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $1148.51 · Aug 31, 2026
LLY 가격 추세
종가
$1148.51
시가
$1168.47
고가
$1171.45
저가
$1147.45
30초 브리핑
LLY 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 94%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 24.5배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
LLY 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Lilly Corporate Center · Indianapolis, IN, United States · 직원 50,000명
시가총액
$1.03T
Trailing P/E
39.4
최근 12개월 이익 기준
Forward P/E
24.5
이익 증가 기대 반영
EPS (TTM)
$29.84
배당 수익률
0.59%
배당성향
21.7%
베타
0.51
시장보다 방어적
ROE
102.3%
P/B
30.44
EV/EBITDA
26.2
52주 범위
$712.05 – $1292.65
현재 위치 94%
거래량
1.88M
20일 평균 1.97M · 1.0배
애널리스트 의견
매수 80%
총 30명 · 0m
동종 커버리지
PEER_SETS에 정의된 동종 그룹 안에서만 비교합니다. MSFT↔WMT 같은 교차 섹터 비교는 하지 않습니다.
기준일 2026-08-29
DITM LEAPS Analysis
LLY 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY280121C00630000 | 1/21/28 · 1.4Y | $630.00 | $578.25 | 1.8x | 0.9119 | 8.9% | 2.85% | 55.45% | 32 | 60.59 | |
| LLY280121C00640000 | 1/21/28 · 1.4Y | $640.00 | $570.25 | 1.8x | 0.9086 | 9.4% | 2.89% | 55.15% | 13 | 58.74 | |
| LLY271217C00620000 | 12/17/27 · 1.3Y | $620.00 | $583.00 | 1.8x | 0.9169 | 7.9% | 3.09% | 56.36% | 1 | 57.68 | |
| LLY280121C00720000 | 1/21/28 · 1.4Y | $720.00 | $490.00 | 2.1x | 0.8871 | 10.9% | 3.27% | 49.51% | 30 | 56.16 | |
| LLY280121C00680000 | 1/21/28 · 1.4Y | $680.00 | $539.00 | 1.9x | 0.8945 | 11.6% | 3.34% | 54.06% | 23 | 55.19 | |
| LLY270917C00700000 | 9/17/27 · 1.0Y | $700.00 | $504.00 | 2.1x | 0.8990 | 9.4% | 3.17% | 53.68% | 14 | 53.48 | |
| LLY280121C00700000 | 1/21/28 · 1.4Y | $700.00 | $523.00 | 2.0x | 0.8875 | 12.7% | 3.44% | 53.30% | 26 | 53.48 | |
| LLY270917C00680000 | 9/17/27 · 1.0Y | $680.00 | $521.00 | 2.0x | 0.9058 | 8.5% | 2.69% | 54.62% | 0 | 52.75 | |
| LLY271217C00730000 | 12/17/27 · 1.3Y | $730.00 | $493.00 | 2.1x | 0.8796 | 13.4% | 3.65% | 51.97% | 12 | 50.22 | |
| LLY271217C00720000 | 12/17/27 · 1.3Y | $720.00 | $505.00 | 2.0x | 0.8804 | 13.5% | 3.56% | 53.73% | 10 | 49.36 | |
| LLY280121C00750000 | 1/21/28 · 1.4Y | $750.00 | $485.00 | 2.1x | 0.8680 | 16.1% | 3.71% | 51.86% | 28 | 48.25 | |
| LLY271217C00760000 | 12/17/27 · 1.3Y | $760.00 | $471.70 | 2.1x | 0.8661 | 15.9% | 3.26% | 51.62% | 37 | 47.57 | |
| LLY280121C00760000 | 1/21/28 · 1.4Y | $760.00 | $477.85 | 2.1x | 0.8637 | 17.0% | 3.41% | 51.67% | 36 | 47.39 | |
| LLY270917C00740000 | 9/17/27 · 1.0Y | $740.00 | $472.00 | 2.2x | 0.8828 | 11.7% | 3.39% | 52.48% | 1 | 46.27 | |
| LLY270917C00780000 | 9/17/27 · 1.0Y | $780.00 | $439.57 | 2.3x | 0.8662 | 14.3% | 3.45% | 50.87% | 8 | 44.19 | |
| LLY280121C00800000 | 1/21/28 · 1.4Y | $800.00 | $447.00 | 2.2x | 0.8474 | 20.2% | 4.03% | 50.14% | 88 | 44.14 | |
| LLY271217C00800000 | 12/17/27 · 1.3Y | $800.00 | $442.00 | 2.2x | 0.8486 | 19.3% | 3.62% | 50.50% | 20 | 42.26 | |
| LLY270917C00800000 | 9/17/27 · 1.0Y | $800.00 | $424.47 | 2.3x | 0.8566 | 16.0% | 2.86% | 50.37% | 11 | 42.10 | |
| LLY280616C00800000 | 6/16/28 · 1.8Y | $800.00 | $472.00 | 2.1x | 0.8425 | 24.4% | 3.39% | 50.21% | 4 | 41.63 | |
| LLY271217C00790000 | 12/17/27 · 1.3Y | $790.00 | $454.00 | 2.2x | 0.8503 | 19.2% | 3.52% | 52.16% | 4 | 40.11 |
재무제표
LLY 연간 손익·현금흐름·재무상태
매출 성장률
+44.7%
최근 연간 YoY
EPS 성장률
+96.0%
최근 연간 YoY
영업이익률
45.6%
최근 연간
FCF 마진
9.2%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $65.18B+44.7% | $45.04B+32.0% | $34.12B+19.6% | $28.54B |
| 매출총이익 | $54.13B+47.8% | $36.63B+35.4% | $27.04B+23.4% | $21.91B |
| 영업이익 | $29.70B+74.3% | $17.04B+65.0% | $10.32B+24.7% | $8.28B |
| 순이익 | $20.64B+94.9% | $10.59B+102.1% | $5.24B-16.1% | $6.24B |
| 희석 EPS | $22.95+96.0% | $11.71+101.9% | $5.80-11.7% | $6.57 |
| EBITDA | $31.69B+68.5% | $18.81B+58.7% | $11.85B+36.9% | $8.66B |
| 영업현금흐름 | $16.81B+90.7% | $8.82B+108.0% | $4.24B-44.1% | $7.59B |
| 잉여현금흐름 | $5.96B+1340.6% | $414.00M+113.1% | -$3.15B-168.5% | $4.60B |
| 총자산 | $112.48B+42.9% | $78.72B+23.0% | $64.01B+29.3% | $49.49B |
| 총부채 | $42.50B+26.3% | $33.64B+33.4% | $25.23B+55.3% | $16.24B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
LLY 실적·배당 일정
매출 하단
$20.98B
EPS 하단
$8.95
매출 상단
$24.04B
배당 지급일
2026-09-10
D-9
실적 발표일
2026-10-29
D-58
EPS 상단
$11.31
매출 컨센서스
$22.23B
EPS 컨센서스
$9.87
배당락일
2026-08-14
18일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 14, 2026 | $1.7300 |
| May 15, 2026 | $1.7300 |
| Feb 13, 2026 | $1.7300 |
| Nov 14, 2025 | $1.5000 |
| Aug 15, 2025 | $1.5000 |
| May 16, 2025 | $1.5000 |
| Feb 14, 2025 | $1.5000 |
| Nov 15, 2024 | $1.3000 |
뉴스
LLY 관련 최신 기사
- M&A
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Stocktwits · Sep 1, 2026
- 제품·기술
Lilly's $2.88 Billion Immunology Deal Starts in Phase 1
The milestone-heavy purchase adds a broad scientific platform, but its lead medicine remains at the earliest clinical stage.
GuruFocus.com · Sep 1, 2026
M&AEli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?
Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026. The acquisition expands Lilly’s immunology pipeline and gives it access to Merida’s antibody-engineering platform, which is […]
Insider Monkey · Aug 31, 2026
제품·기술Chris Benecchi Named Inventiva’s New Chief Operating Officer
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.
Exec Edge · Aug 31, 2026
M&AEli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.
Motley Fool · Aug 31, 2026
- 일반
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a
MT Newswires · Aug 31, 2026
M&ALilly Is Bigger Than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.
Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.
Barrons.com · Aug 31, 2026
M&AA $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today
Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.
Barchart · Aug 31, 2026
제품·기술Nvidia’s Scarcity Runs Out in Five Years: ‘A Chip Designed by OpenAI, by AI’
OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia's most valuable competitive advantage disappears entirely.
24/7 Wall St. · Aug 31, 2026
주주환원This Popular Healthcare ETF Is Diluting Your Dividend Income
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.
24/7 Wall St. · Aug 31, 2026
홀더
LLY 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
85.4%
기관 보유 (유동주식)
85.6%
내부자 보유
0.2%
기관 수
5,874
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Lilly Endowment, Inc | 90.38M | $104.54B | 9.6% | -1.7% | Jun 30, 2026 |
| Blackrock Inc. | 67.54M | $78.13B | 7.2% | 1.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 53.53M | $61.92B | 5.7% | 0.3% | Jun 30, 2026 |
| PNC Financial Services Group, Inc. | 51.32M | $59.37B | 5.5% | -0.0% | Jun 30, 2026 |
| State Street Corporation | 36.22M | $41.89B | 3.9% | 1.7% | Jun 30, 2026 |
| FMR, LLC | 28.46M | $32.92B | 3.0% | 8.1% | Jun 30, 2026 |
| Capital Research Global Investors | 20.87M | $24.14B | 2.2% | -15.3% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 20.86M | $24.13B | 2.2% | -0.6% | Jun 30, 2026 |
| Geode Capital Management, LLC | 20.31M | $23.49B | 2.2% | 0.6% | Jun 30, 2026 |
| Morgan Stanley | 16.23M | $18.77B | 1.7% | 5.1% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.